If you have mild cognitive impairment (MCI) and your clinician has offered a blood biomarker test, the results you get back will not be a yes-or-no verdict on Alzheimer's disease. The AAIC 2026 findings sharpen two things: how accurately these tests identify Alzheimer's biology, and how much a number predicts about what happens next — which is less than most people expect, and more than nothing.
MCI means measurable memory or thinking problems that have not yet taken away independence. The blood test most often discussed is plasma p-tau217, a form of tau protein that rises when Alzheimer's-related changes are underway in the brain. The questions below are the ones worth asking in the appointment where your result is explained.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the AAIC 2026 results actually added
- "Elevated" is not one answer — ask where in the range you fall
- Which test was run, and what it is allowed to decide
- What a positive result changes about your prognosis
- Getting the result sooner, and whether it is distressing
- Limits to hold onto
- Frequently Asked Questions
What the AAIC 2026 results actually added
The headline finding came from a pooled analysis of about 2,700 cognitively unimpaired older adults, presented at AAIC 2026 in London and published simultaneously in JAMA. According to the Alzheimer's Association release on that analysis, each standard-deviation rise in plasma p-tau217 carried a 38% higher hazard of progressing to clinical impairment, and very high levels implied roughly a 78% risk over ten years — about one in three over five. That study enrolled people without symptoms, so its risk percentages are not your percentages if you already have MCI.
What it establishes is that the marker tracks real disease trajectory rather than noise, which is the foundation for using it in people who do have symptoms. The second AAIC 2026 result is the one that bears directly on diagnosis. A Swedish study of 1,310 patients and 165 physicians using the PrecivityAD2 p-tau217 test lifted primary-care diagnostic accuracy from 65% to 94%, and specialist accuracy from 76% to 93%, and changed clinical management in 49.2% of patients. The gap between primary care and specialists essentially closed after the result was disclosed.
"Elevated" is not one answer — ask where in the range you fall
The single most useful question to ask is where your number sits, not whether it crossed a line. In the same pooled analysis, the Alzheimer Europe summary of the AAIC 2026 results reports that people with only mildly elevated p-tau217 had an estimated 15% risk at five years and 45% at ten — against 33% and 78% for the very high group. Those are different conversations about different futures, delivered by the same word.
A result reported to you as simply "positive" or "elevated" has had its most informative detail stripped out. There is also a middle zone where the test answers least. Alzforum's coverage of the 2026 trial data notes that p-tau217 was most informative when clearly low or clearly high, and least informative in the intermediate range, where a result neither rules Alzheimer's in nor out and further testing is needed. Fewer than 20% of results fall into the indeterminate bin on the FDA-cleared assay, but if yours does, that is a finding about the test, not a hidden diagnosis.
Which test was run, and what it is allowed to decide
"How good is this blood test?" has no general answer. It depends on the specific assay, and the Alzheimer's Association has warned that many commercially available blood biomarker tests do not meet published accuracy thresholds.
The 2025 Alzheimer's Association clinical practice guideline — written for exactly your situation, people with MCI or dementia in specialty care — sets two tiers: The guideline's recommendations are conditional and rest on low-certainty evidence, which is itself worth knowing. The first FDA-cleared option is Fujirebio's Lumipulse G pTau217/β-Amyloid 1-42 plasma ratio; per the FDA clearance announcement from May 2025, it is intended for adults 55 and older with signs of cognitive decline, and in 499 samples 91.7% of positive and 97.3% of negative results matched PET or CSF. Questions to bring: Which assay was used? Is it being used as triage or as confirmation? If triage, what is the plan for confirmation?.
- A **triage** test needs at least 90% sensitivity and 75% specificity. A positive triage result still requires amyloid PET imaging or a cerebrospinal fluid (CSF) test to confirm it.
- A **confirmatory** test needs at least 90% sensitivity and 90% specificity. Only a test at that level substitutes for PET or CSF.
What a positive result changes about your prognosis
A positive amyloid or tau result moves your odds; it does not fix your future. In a three-year study of amnestic MCI published in Scientific Reports, amyloid-positive patients progressed to dementia at roughly 21% per year against about 6% for amyloid-negative patients — a hazard ratio of 3.74, though the sample was only 47 people and the confidence interval was wide. Read that as a meaningful shift in likelihood from a small study, not as a timeline.
Plenty of amyloid-positive people with MCI remain stable for years, and some amyloid-negative people decline from other causes, including vascular disease, medication effects, sleep disorders, and depression — several of which are treatable. The practical value of the result is often the opposite of what people fear. A negative test can redirect the whole workup toward a cause that can be acted on. A positive test can establish eligibility for anti-amyloid treatment and for trials, both of which require confirmed Alzheimer's biology.
Getting the result sooner, and whether it is distressing
Waiting does not protect anyone. The PLASMAR randomized trial of 220 memory-clinic patients with subjective decline, MCI, or mild dementia, reported in JAMA Neurology in October 2026, disclosed p-tau217 and NfL results at three months instead of nine. The share of patients with a high-confidence diagnosis of cause — at least 90% certainty — rose from 4.6% to 50%, and about a quarter of diagnoses changed.
Crucially, early disclosure did not increase anxiety or depression scores. That finding is a reasonable answer to "should I even want to know this?" — in a randomized setting, knowing earlier was not the harm people anticipate. NfL, the other marker in that trial, is neurofilament light chain: a general signal of nerve-cell damage that is not specific to Alzheimer's. It helps distinguish Alzheimer's from other neurological causes rather than confirming it.
Limits to hold onto
The AAIC 2026 results are labeled preliminary by the Alzheimer's Association, pending peer review, and the Association is explicit that this approach is not ready to replace a comprehensive clinical evaluation. A blood number does not replace cognitive testing, a history, an exam, and imaging where indicated. The Association also advises that these tests be ordered by a clinician only for people already experiencing memory or thinking problems — not as a screen for adults without symptoms.
If a family member without symptoms asks whether they should get tested after reading the ten-year risk figures, that is the line to point to. One more thing to confirm before you leave the appointment: ask for your actual value and the laboratory's reference range in writing. A result recorded only as "elevated" cannot be compared against the risk tiers above, and cannot be re-read by the next clinician who sees you.
Frequently Asked Questions
Does a positive blood test mean I have Alzheimer's disease?
Not on its own. Under the 2025 Alzheimer's Association guideline, a positive triage-tier result still requires amyloid PET or CSF confirmation; only a test meeting 90% sensitivity and 90% specificity stands in for those.
My result came back in the middle. What now?
The intermediate zone is where p-tau217 is least informative, and further testing is the expected next step rather than a sign something went wrong. Ask specifically which confirmatory test is planned.
Can I ask for the test if I have no symptoms but a family history?
The Alzheimer's Association advises against using these tests to screen people without memory or thinking problems. The ten-year risk figures came from a research cohort, not from clinical screening practice.
Will a diagnosis of Alzheimer's biology change my treatment?
In the Swedish AAIC 2026 study, disclosure changed clinical management in 49.2% of patients. Confirmed Alzheimer's biology is also a requirement for anti-amyloid therapy and for most treatment trials.
You Might Also Like
- AAIC 2026 Primary Care Alzheimer’s Blood Test Findings: Result Interpretation Questions for People With Mild Cognitive Impairment
- Tauklarify Tau PET vs Amyloid PET After the 2026 Approval: Accuracy, Limits, and Evidence Gaps for People With Mild Cognitive Impairment
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: A Source-Checked Briefing for People With Mild Cognitive Impairment
